| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Zhiwen Yu, Tianru Ji. New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 (GLP-1). Cellular signalling. vol 22. issue 1. 2009-12-14. PMID:19772917. |
the incretin hormone glp-1 stimulates insulin secretion and pro-insulin gene transcription. |
2009-12-14 |
2023-08-12 |
Not clear |
| Zhiwen Yu, Tianru Ji. New insights into the role of cAMP in the production and function of the incretin hormone glucagon-like peptide-1 (GLP-1). Cellular signalling. vol 22. issue 1. 2009-12-14. PMID:19772917. |
glp-1 also enhances pancreatic beta-cell proliferation, inhibits cell apoptosis, and has been utilized in the trans-differentiation of insulin producing cells. |
2009-12-14 |
2023-08-12 |
Not clear |
| Mark Kirby, Denise M T Yu, Steven O'Connor, Mark D Gorrel. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clinical science (London, England : 1979). vol 118. issue 1. 2009-12-02. PMID:19780719. |
dpp-4 (dipeptidyl peptidase-4) degrades the incretin hormones glp-1 (glucagon-like peptide-1) and gip (gastric inhibitory polypeptide), decreasing their stimulatory effects on beta-cell insulin secretion. |
2009-12-02 |
2023-08-12 |
Not clear |
| Sarah Melissa P Jacobo, Marcy L Guerra, Gregory H Hockerma. Cav1.2 and Cav1.3 are differentially coupled to glucagon-like peptide-1 potentiation of glucose-stimulated insulin secretion in the pancreatic beta-cell line INS-1. The Journal of pharmacology and experimental therapeutics. vol 331. issue 2. 2009-11-30. PMID:19710366. |
the incretin peptides, glucose-dependent insulinotropic polypeptide (gip) and glucagon-like peptide-1 (glp-1), potentiate glucose-stimulated insulin secretion (gsis) and beta-cell proliferation and differentiation. |
2009-11-30 |
2023-08-12 |
Not clear |
| Selda Gezginci-Oktayoglu, Sehnaz Bolken. Exendin-4 exerts its effects through the NGF/p75NTR system in diabetic mouse pancreas. Biochemistry and cell biology = Biochimie et biologie cellulaire. vol 87. issue 4. 2009-11-27. PMID:19767827. |
glucagon-like peptide-1 (glp-1) ameliorates the symptoms of diabetes through stimulation of insulin secretion. |
2009-11-27 |
2023-08-12 |
mouse |
| Rolf Mentlei. Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP. Best practice & research. Clinical endocrinology & metabolism. vol 23. issue 4. 2009-11-23. PMID:19748062. |
the incretin hormones glucagon-like peptide-1 (glp-1) and glucose-dependent insulinotropic peptide (gip, gastric inhibitory peptide) are secreted from intestinal l and k cells and stimulate insulin secretion from pancreatic beta cells. |
2009-11-23 |
2023-08-12 |
Not clear |
| Tina Vilsbøll, Jens J Holst, Filip K Kno. The spectrum of antidiabetic actions of GLP-1 in patients with diabetes. Best practice & research. Clinical endocrinology & metabolism. vol 23. issue 4. 2009-11-23. PMID:19748063. |
therefore, the actions of glp-1, which include the potentation of meal-induced insulin secretion and trophic effects on the beta-cell, have attracted a lot of interest. |
2009-11-23 |
2023-08-12 |
Not clear |
| Sten Madsba. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best practice & research. Clinical endocrinology & metabolism. vol 23. issue 4. 2009-11-23. PMID:19748064. |
the glp-1 analogues exenatide and liraglutide stimulate insulin secretion and inhibit glucagon output in a glucose-dependent manner, slow gastric emptying and decrease appetite. |
2009-11-23 |
2023-08-12 |
human |
| Bo Ahré. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events. Best practice & research. Clinical endocrinology & metabolism. vol 23. issue 4. 2009-11-23. PMID:19748066. |
dpp-4 inhibition increases insulin secretion and reduces glucagon secretion by preventing the inactivation of glucagon-like peptide-1 (glp-1), thereby lowering glucose levels. |
2009-11-23 |
2023-08-12 |
human |
| Harald Sourij, Isabella Schmölzer, Eva Kettler-Schmut, Michaela Eder, Helga Pressl, Antonella Decampo, Thomas C Wasche. Efficacy of a continuous GLP-1 infusion compared with a structured insulin infusion protocol to reach normoglycemia in nonfasted type 2 diabetic patients: a clinical pilot trial. Diabetes care. vol 32. issue 9. 2009-11-16. PMID:19528368. |
efficacy of a continuous glp-1 infusion compared with a structured insulin infusion protocol to reach normoglycemia in nonfasted type 2 diabetic patients: a clinical pilot trial. |
2009-11-16 |
2023-08-12 |
Not clear |
| Natalie D Luscombe-Marsh, Astrid J P G Smeets, Margriet S Westerterp-Planteng. The addition of monosodium glutamate and inosine monophosphate-5 to high-protein meals: effects on satiety, and energy and macronutrient intakes. The British journal of nutrition. vol 102. issue 6. 2009-11-13. PMID:19267954. |
appetite perceptions, plasma concentrations of glucagon-like peptide 1 (glp-1), glucose and insulin, and energy intake at a buffet (i.e. |
2009-11-13 |
2023-08-12 |
Not clear |
| Natalie D Luscombe-Marsh, Astrid J P G Smeets, Margriet S Westerterp-Planteng. The addition of monosodium glutamate and inosine monophosphate-5 to high-protein meals: effects on satiety, and energy and macronutrient intakes. The British journal of nutrition. vol 102. issue 6. 2009-11-13. PMID:19267954. |
changes in appetite, and in glp-1, glucose and insulin, were similar for the three fed hp conditions and all were greater (post hoc all p < 0.01) than the control and sham conditions. |
2009-11-13 |
2023-08-12 |
Not clear |
| Marie-Line Peyot, Joshua P Gray, Julien Lamontagne, Peter J S Smith, George G Holz, S R Murthy Madiraju, Marc Prentki, Emma Hear. Glucagon-like peptide-1 induced signaling and insulin secretion do not drive fuel and energy metabolism in primary rodent pancreatic beta-cells. PloS one. vol 4. issue 7. 2009-11-10. PMID:19593440. |
glucagon like peptide-1 (glp-1) and its analogue exendin-4 (ex-4) enhance glucose stimulated insulin secretion (gsis) and activate various signaling pathways in pancreatic beta-cells, in particular camp, ca(2+) and protein kinase-b (pkb/akt). |
2009-11-10 |
2023-08-12 |
Not clear |
| Kevin Dochert. Pancreatic stellate cells can form new beta-like cells. The Biochemical journal. vol 421. issue 2. 2009-11-05. PMID:19552623. |
when plated on extracellular matrix, along with a cocktail of growth factors that included insulin, transferrin, selenium and the glp-1 (glucagon-like peptide-1) analogue exendin-4, the cells differentiated into cells that expressed many of the phenotypic markers characteristic of a beta-cell, and exhibited an insulin-secretory response, albeit weak, to glucose. |
2009-11-05 |
2023-08-12 |
human |
| C K Martin, H Han, S D Anton, F L Greenway, S R Smit. Effect of valproic acid on body weight, food intake, physical activity and hormones: results of a randomized controlled trial. Journal of psychopharmacology (Oxford, England). vol 23. issue 7. 2009-11-04. PMID:18583434. |
glucose levels and hormones [peptide yy(3-36), glucagon-like peptide-1 (glp-1), leptin, ghrelin, insulin] that regulate ei were measured. |
2009-11-04 |
2023-08-12 |
human |
| Adam M Deane, Marianne J Chapman, Robert J L Fraser, Carly M Burgstad, Laura K Besanko, Michael Horowit. The effect of exogenous glucagon-like peptide-1 on the glycaemic response to small intestinal nutrient in the critically ill: a randomised double-blind placebo-controlled cross over study. Critical care (London, England). vol 13. issue 3. 2009-10-28. PMID:19439067. |
in healthy patients and those with type 2 diabetes, exogenous glucagon-like peptide-1 (glp-1) decreases blood glucose by suppressing glucagon, stimulating insulin and slowing gastric emptying. |
2009-10-28 |
2023-08-12 |
Not clear |
| E J Verspoh. Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors. Pharmacology & therapeutics. vol 124. issue 1. 2009-10-28. PMID:19545590. |
the incretin glp-1 helps to maintain glucose homeostasis through stimulation of insulin secretion and inhibition of glucagon release in a glucose-dependent manner. |
2009-10-28 |
2023-08-12 |
Not clear |
| Janet B McGil. Selecting among ADA/EASD tier 1 and tier 2 treatment options. The Journal of family practice. vol 58. issue 9 Suppl Treating. 2009-10-05. PMID:19744422. |
each of the 4 groups of medications considered preferred therapies for treatment of t2dm by the ada/easd panel--insulin, sulfonylureas, tzds, and incretin-based therapies (glp-1 receptor agonists)--possesses significant advantages and disadvantages to be considered when individualizing treatment. |
2009-10-05 |
2023-08-12 |
Not clear |
| Mansur E Shomal. Practical applications of therapy with a glucagon-like peptide-1 receptor agonist. The Journal of family practice. vol 58. issue 9 Suppl Treating. 2009-10-05. PMID:19744424. |
the 4 groups of medications recommended by the ada/easd panel as the preferred therapies are basal insulin, the sulfonylureas, the tzd pioglitazone, and glp-1 receptor agonists. |
2009-10-05 |
2023-08-12 |
Not clear |
| Seung-Ryoung Jung, Benjamin J Reed, Ian R Swee. A highly energetic process couples calcium influx through L-type calcium channels to insulin secretion in pancreatic beta-cells. American journal of physiology. Endocrinology and metabolism. vol 297. issue 3. 2009-09-30. PMID:19584201. |
in the presence of nimodipine or kn-62, potentiators of isr, acetylcholine, glp-1, and arginine had little effect on insulin secretion, suggesting that the cmcp is also essential for the amplification of isr. |
2009-09-30 |
2023-08-12 |
rat |